ArticleFrontiers in immunology2025
Dual-functional cerium oxide nanoparticles with antioxidant and DNase I activities to prevent and degrade neutrophil extracellular traps.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Neutrophil Extracellular Traps in the Tumor Microenvironment: Mechanisms, Immune Regulation, and Implications for Immune Checkpoint Inhibitor Therapy.International journal of molecular sciences · 2026Review
- Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Eosinophil Extracellular Traps in Health and Disease: From Host Defense to Chronic Inflammation.Biomedicines · 2026Review
- Nanozymes in the Treatment of Pediatric Inflammatory Diseases: Opportunities and Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.Advanced healthcare materials · 2026Review
- Cell death crosstalk in NET-Driven inflammation: mechanisms, disease contexts, and therapeutic perspectives.Biomarker research · 2026Review
- Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting.Biomarker research · 2026Review
- Neutrophils and NETosis in polycystic ovary syndrome: unraveling the immuno-metabolic thromboinflammatory axis.European journal of medical research · 2026Review
- Activation of the cGAS-STING Pathway by NETs Promotes Inflammatory Injury in Myocardial Ischemia-Reperfusion.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophils play a central role in immunothrombosis through the formation of neutrophil extracellular traps (NETs), a process known as NETosis. Upon stimulation, neutrophils release decondensed chromatin structures enriched with proteolytic enzymes, which contribute to thrombus formation. NETosis is critically dependent on reactive oxygen species (ROS), making redox regulation a key point of intervention. The intrinsic redox cycling of cerium oxide nanoparticles (CNPs) imparts self-regenerating antioxidant properties suitable for modulating neutrophil-driven oxidative stress. To address both the prevention and clearance of NETs, we developed dual-functional CNPs conjugated with DNase I. These engineered nanoparticles were efficiently internalized by neutrophils, reduced intracellular ROS levels, and inhibited NETs formation. In addition, DNase I-functionalized CNPs degraded pre-formed NETs. This dual-action strategy offers a promising nanotherapeutic platform for mitigating NETs-associated thrombotic pathologies. Ongoing studies aim to enhance thrombus targeting and assess
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.